Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients

American Journal of Transplantation

Volumn 13, Issue 9, 2013, Pages 2402-2410

  Manuel, O ^a   Kralidis, G ^b   Mueller, N J ^c   Hirsch, H H ^d,e   Garzoni, C ^f,g   Van Delden, C ^h   Berger, C ⁱ   Boggian, K ^j   Cusini, A ^f   Koller, M T ^b   Weisser, M ^d   Pascual, M ^a   Meylan, P R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g Reparto di Chirurgia Ortopedica   (Switzerland)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^j Hospital Hygiene   (Switzerland)

more..

Author keywords

Antiviral prophylaxis; graft loss; indirect effects; preemptive therapy; valganciclovir

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAZARD RATIO; HEART TRANSPLANTATION; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIVIRAL PROPHYLAXIS; GRAFT LOSS; INDIRECT EFFECTS; PREEMPTIVE THERAPY; VALGANCICLOVIR;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84883453128     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12388     Document Type: Article

References (35)

1. Humar A, Snydman D, Practice ASTIDCo. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S78-S86.
2. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
3. Meylan PR, Manuel O., Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007; 20: 412-418.
4. Freeman RB Jr., The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009; 9: 2453-2458.
5. Helantera I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH., Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010; 24: 339-371.
6. Manuel O, Perrottet N, Pascual M., Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. Expert Rev Anti Infect Ther 2011; 9: 955-965.
7. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105-2115.
8. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG, Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880.
9. Atabani SF, Smith C, Atkinson C, et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012; 12: 2457-2464.
10. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
11. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F., Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983.
12. Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 2012; 23: 1588-1597.
13. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V., Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69-77.
14. Witzke O, Hauser IA, Bartels M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-Year results of a randomized clinical trial. Transplantation 2012; 93: 61-68.
15. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
16. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
17. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846.
18. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652.
19. Koller MT, van Delden C, Müller NJ, et al. Design and methodology of the Swiss Transplant Cohort Study (STCS): A comprehensive prospective nationwide long-term follow-up cohort. Eur J Epidemiol 2013, 28: 347-355.
20. Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009; 14: 697-704.
21. Humar A, Michaels M., Monitoring AIWGoID. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
22. Allignol A, Beyersmann J., Software for fitting nonstandard proportional subdistribution hazards models. Biostatistics 2010; 11: 674-675.
23. Koller MT, Raatz H, Steyerberg EW, Wolbers M., Competing risks and the clinical community: Irrelevance or ignorance ? Stat Med 2012; 31: 1089-1097.
24. Ruan PK, Gray RJ., Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med 2008; 27: 5709-5724.
25. R Development Core Team. A language and environment for statistical computing. Available from: http://www.R-project.org 2012.
26. San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47: 875-882.
27. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152: 761-769.
28. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E, et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 2011; 91: 927-933.
29. Singh N, Wannstedt C, Keyes L, et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 2008; 14: 240-244.
30. Couzi L, Helou S, Bachelet T, et al. High incidence of anticytomegalovirus drug resistance among D + R-kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012; 12: 202-209.
31. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD., Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.
32. Sagedal S, Hartmann A, Rollag H., The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect 2005; 11: 518-530.
33. Opelz G, Dohler B, Ruhenstroth A., Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928-936.
34. Greiner M, Cusini A, Ruesch M, et al. A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. Infection 2012; 40: 669-675.
35. Kunzle N, Petignat C, Francioli P, et al. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: Relationship between compliance with the guidelines and prevention of CMV morbidity. Transpl Infect Dis 2000; 2: 118-126.